Success Metrics

Active Trials
2(40%)

Phase Distribution

Ph early_phase_1
1
20%
Ph not_applicable
1
20%
Ph phase_1
3
60%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
3(60.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Other(3)

Detailed Status

unknown3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (20.0%)
Phase 13 (60.0%)
N/A1 (20.0%)

Trials by Status

unknown360%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingnot_applicable

IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)

NCT06513429
unknownearly_phase_1

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

NCT05480501
unknownphase_1

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

NCT05309213
unknownphase_1

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

NCT05155215
recruitingphase_1

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

NCT04440436

Clinical Trials (5)

Showing 5 of 5 trials
NCT06513429Not Applicable

IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)

Recruiting
NCT05480501Early Phase 1

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Unknown
NCT05309213Phase 1

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Unknown
NCT05155215Phase 1

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Unknown
NCT04440436Phase 1

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5